Allergan and Editas announce $90M CRISPR deal
There really is enough CRISPR to go around. On Tuesday Allergan and Editas struck a deal to apply the gene-editing approaching in certain ocular conditions, including Leber congenital amaurosis.
Editas breathes sigh of relief as CRISPR ruling handed down
A ruling on the high-profile CRISPR patent interference case was delivered Wednesday, sending Editas shares up and causing others to dive. For all involved, the show will go on as other CRISPR licensing agreements still stand.
presented by
6 Aesthetic Certification Programs That Include Both Theory and Practical Training
Explore top-tier aesthetic certification programs that blend theory with hands-on training — perfect for health care pros ready to elevate their practice
Is innovation a kind of intellectual immigration?
Flagship Ventures is now Flagship Pioneering, a rebrand that its CEO says better reflects its mission to discover and build first-of-its-kind science. It's a journey into the unknown — a journey that many U.S. innovators have taken before.
A silver lining in the CRISPR court case
On Tuesday, judges heard verbal arguments from both sides of the CRISPR intellectual property fight, a technology that could prove to be the greatest biotech advance in recent history. But the outcome matters less than what is happening in the field right now.
Morning Read: Valeant and Turing kill themselves with their own e-mails; CRISPR hits the public market with Editas’ $94M in IPO
Also, a new collar device has been designed to help protect athletes from head injuries, and it appears that the Zika virus can be sexually transmitted.